Benefits of specialist severe asthma management: demographic and geographic disparities
Charlene Redmond, Liam G. Heaney, Rekha Chaudhuri, David J. Jackson, Andrew Menzies-Gow, Paul Pfeffer, John Busby on behalf of the UK Severe Asthma Registry
European Respiratory Journal 2022 60: 2200660; DOI: 10.1183/13993003.00660-2022
Abstract
Background The benefits of specialist assessment and management have yet to be evaluated within the biologic era of UK severe asthma treatment, and potential disparities have not been considered.
Methods In an uncontrolled before-and-after study, we compared asthma symptoms (Asthma Control Questionnaire-6 (ACQ-6)), exacerbations, unscheduled secondary care use, lung function (forced expiratory volume in 1 s (FEV1)) and oral corticosteroid (OCS) dose after 1 year. We compared outcomes by sex, age (18–34, 35–49, 50–64 and ≥65 years), ethnicity (Caucasian versus non-Caucasian) and hospital site after adjusting for demographics and variation in biologic therapy use.
Results 1140 patients were followed-up for 1370 person-years from 12 specialist centres. At annual review, ACQ-6 score was reduced by a median (interquartile range (IQR)) of 0.7 (0.0–1.5), exacerbations by 75% (33–100%) and unscheduled secondary care by 100% (67–100%). FEV1 increased by a median (IQR) of 20 (−200–340) mL, while OCS dose decreased for 67% of patients. Clinically meaningful improvements occurred across almost all patients, including those not receiving biologic therapy. There was little evidence of differences across demographic groups, although those aged ≥65 years demonstrated larger reductions in exacerbations (69% versus 52%; p<0.001) and unscheduled care use (77% versus 50%; p<0.001) compared with patients aged 18–34 years. There were >2-fold differences between the best and worst performing centres across all study outcomes.
Conclusions Specialist assessment and management is associated with substantially improved patient outcomes, which are broadly consistent across demographic groups and are not restricted to those receiving biologic therapy. Significant variation exists between hospitals, which requires further investigation.
